High Dose CHOP in Lymphoma

This study has been completed.
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00192764
First received: September 13, 2005
Last updated: September 21, 2010
Last verified: September 2010

September 13, 2005
September 21, 2010
December 1996
Not Provided
Failure-free survival
Same as current
Complete list of historical versions of study NCT00192764 on ClinicalTrials.gov Archive Site
  • overall survival
  • response rate
  • toxicity
Same as current
Not Provided
Not Provided
 
High Dose CHOP in Lymphoma
Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Non-Hodgkin's Lymphoma
Drug: high-dose cyclophosphamide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
September 2010
Not Provided

Inclusion Criteria:

  • large-cell non-Hodgkin's lymphoma
  • IPI low-intermediate, high-intermediate and high or bulky mediastinum
  • age 18-65

Exclusion Criteria:

  • previous treatment for lymphoma
  • serious concurrent systemic disease
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00192764
RonHDCHOP.CTIL
Not Provided
Not Provided
Rambam Health Care Campus
Not Provided
Principal Investigator: Ron Epelbaum, MD nonaffiliated
Rambam Health Care Campus
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP